Agilent Technologies: stocks, financial statements

Disable ads for free
Dividends News

It is engaged in the production of measuring equipment, electronic medical equipment and equipment for chemical analysis. It also develops consumables and independently provides diagnostic services for the chemical composition of various food and medical products. For the state segment, food products are examined for the presence of various types of contamination (viruses, bacteria, chemicals, and microorganisms). In the energy industry, the company conducts research on biofuels as an alternative form of energy.

Environmental and criminal examination reveals the presence of metals, various biological additives and residues of medical drugs in athletes. Pharmaceutical diagnostics helps to create new medicines, check their purity and compliance with standards. Medical diagnostics mainly works in the field of Oncology, cardiovascular diseases, diabetes, but also allows you to quickly provide doctors with the necessary information on other diseases. Most of the company's product lines were developed by Hewlett-Packard.

  • A Ticker
  • NYSE Exchange
  • 14,800 Employees
9 rated
  • $114.35, $-0.33 (-0.29%) Previous Close
  • 2,862,483 Previous Volume
  • $61.13 / $118.96 52 week low / high
  • -3.88% Percent off 52 week high
  • 2020-11-25 Updated
  • 0.63% Dividend Yield (trailing)
  • 0.68% Dividend Yield (forward)
  • 306,624,778 Public float
  • 308,310,000 Outstanding shares
  • 49.14 P/E
  • 35.36 B Market Cap
Disable ads for free

Financial statements — Agilent Technologies

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
5.2B 4.9B 4.5B 4.2B 4B
Cost Of Revenue
2.4B 2.2B 2.1B 2B 2B
Gross Profit
2.8B 2.7B 2.4B 2.2B 2B
Research and Development
400M 390M 340M 330M 330M
Selling General and Admin
1.5B 1.4B 1.2B 1.1B 1.2B
Operating Expense
4.2B 4B 3.6B 3.5B 3.5B
Operating Income
930M 930M 840M 740M 550M
Other Income Expense Net
-15M 15M -37M -190M -68M
930M 930M 840M 740M 550M
Interest Income
73M 74M 79M 72M 66M
Pretax Income
920M 950M 800M 540M 480M
Income Tax
-150M 630M 120M 82M 42M
Minority Interest
0 0 0 0 0
Net Income
1.1B 320M 680M 460M 400M
Net Income Basic
1.1B 320M 680M 460M 400M
19 ← 15 2019 2018 2017 2016 2015
Current cash
1.4B 2.2B 2.7B 2.3B 2.2B
Short term investments
930M 780M 720M 630M 610M
680M 640M 580M 530M 540M
Other current assets
130M 130M 120M 99M 190M
Current assets
3.2B 3.8B 4.2B 3.6B 3.7B
Long term investments
110M 68M 140M 140M 86M
Property plant equipment
850M 820M 760M 640M 600M
3.6B 3B 2.6B 2.5B 2.4B
Intangible assets
1.1B 490M 360M 410M 450M
Other assets
190M 160M 140M 63M 92M
Total assets
9.5B 8.5B 8.4B 7.8B 7.5B
Accounts payable
350M 340M 310M 260M 280M
Current long term debt
Other current liabilities
820M 760M 690M 640M 630M
Total current liabilities
2.1B 1.2B 1.3B 950M 980M
Long term debt
1.8B 1.8B 1.8B 1.9B 1.7B
Other liabilities
800M 930M 220M 270M 320M
Minority Interest
0 0 0 0 0
Total Liabilities
4.7B 4B 3.6B 3.6B 3.3B
Common stock
310M 320M 320M 320M 330M
Retained earning
-18M -340M -130M 6.1B 5.6B
Treasury stock
1.5M 1.3M 1.1M 1.1M 1.4M
Capital surplus
5.3B 5.3B 5.3B 9.2B 9B
Shareholder equity
4.7B 4.6B 4.8B 4.2B 4.2B
Net tangible assets
-4.5B -2.7B -1.6B -2B -1.7B
19 ← 15 2019 2018 2017 2016 2015
Net Income
1.1B 320M 680M 460M 400M
240M 210M 210M 250M 250M
Changes in receivables
-150M -52M -93M -25M
Changes in inventories
-36M -83M -61M -7M -24M
Cash change
-870M -430M 390M 41M -220M
Cash flow
1B 1.1B 890M 790M 490M
Capital expenditures
-160M -180M -180M -140M -98M
-23M -11M -1M -82M -1M
Investing activity other
-3M -2M -1M -1M -240M
Total investing cash flows
-1.6B -710M -300M -480M 410M
Dividends paid
-210M -190M -170M -150M -130M
Net borrowings
600M -210M 110M 260M
Other financing cash flows
-14M -6M -730M
Cash flow financing
-300M -800M -200M -270M -1.1B
Exchange rate effect
2M -17M 7M -1M -48M
Disable ads for free
Disable ads for free